Keyword: Johns Hopkins

With a new, privately funded research center, Johns Hopkins is trying to jump-start psychedelic research that has been stymied since the 1970s.

Johns Hopkins scientists found that misfolded alpha-synuclein protein can travel from the gut and drive Parkinson's disease.

A combination of Viracta Therapeutics' nanatinostat and an antiviral drug produced a 58% response rate in an early trial.

Thrive debuted with $110 million, liquid biopsy technology from Johns Hopkins and Third Rock's Steve Kafka at the helm to catch cancer earlier.

Donald Hayden, who joined WindMIL Therapeutics as executive chairman and then interim CEO, will become the company's permanent CEO.

Sonavex scored FDA clearance for its technology that uses ultrasound imaging and deep learning to deliver blood flow data on demand.

Brain scans of more than 30,000 individuals showed cerebral blood flow fluctuation related to age.

Suppressing the YAP protein, known for its role in modulating cell death, may help free up the immune system to fight cancer.

A startup from Johns Hopkins launched with $36 million to bring a potentially disease-modifying drug into phase 1 for Parkinson’s disease.

The past week saw the discovery of a genetic mutation that disrupts nerve signaling in ALS and the development of a noninvasive bladder cancer test.